Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different types of NET. However, it is can cause severe adverse effects. Phase I trial demonstrated that a dose of 5mg/day/week was sufficient to inhibit cell proliferation by blocking the mTOR pathway.

This is a randomized, open-label, phase II near-equivalence clinical trial of oral everolimus 5 mg vs 10 mg oral/daily and continuously in patients with Grade 1 or Grade 2 metastatic NET, with tumor progression or intolerance to at least one line of treatment and with radiological disease progression within 6 months.

Everolimus toxicity can also be serious, requiring hospital medical assistance. In a study with more than 100 Latin American patients led by our group, approximately 20% of patients with NET treated with everolimus 10mg/day had serious infections, such as pneumonia, abscesses, pyelonephritis, with 7% developing opportunistic infections, such as toxoplasmosis and pneumocystosis, requiring hospital admissions.

The rationale for testing 5mg/day comes from the results of phase I trials of everolimus, where a dose of 5mg/day was sufficient to inhibit cell proliferation by blocking the mTOR pathway.

Therefore, everolimus 5mg/day appears to have antitumor effects equivalent to 10mg/day, but it is less toxic than 10mg/day. Retrospective data from our center also suggest that 5mg is similar to 10mg/daily in terms of time to treatment failure in patients with advanced NETs (unpublished data).

Objectives:

• To evaluate whether everolimus at a dose of 5 mg/day may be as effective, but safer, as 10 mg/day in the treatment of patients with advanced NET.
• To compare progression-free survival and time to treatment failure between study arms
• To compare radiological response using RECIST v.1.1 criteria.
• To compare the frequency of grade > 1 toxicities using CTCAE v.5.0.
• To assess tolerability by measuring the frequency and intensity of adverse events measured by the CTCAE version 5.0 criteria and the need for temporary or permanent interruption of everolimus.

Methods:

Randomized, open-label, phase II near-equivalence clinical trial of oral everolimus 5 mg vs 10 mg oral/daily and continuously in patients with Grade 1 or Grade 2 metastatic NET, with tumor progression or intolerance to at least one line of treatment and with radiological disease progression within 6 months.

Eligibility criteria:

Inclusion:

• Histological confirmation of well-differentiated Grade 1/Grade 2 NET from gastrointestinal, pancreatic, pulmonary or unknown primary sites.

• Metastatic or locally advanced and unresectable disease, measurable by images

• Disease progression by RECIST 1.1 in the last 6 months assessed by local investigators

• At least one previous line of systemic treatment (suspended for more than 3 weeks).

• Eastern Cooperative Oncology Group (ECOG) 0-2

• Good organ function:

  • Hemoglobin > 8 g/dL
  • Neutrophils ≥ 1,500/mm³
  • Platelets > 90,000/mm³
  • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN [upper limit of normal] or ≤ 5 x ULN for patients with liver metastases
  • Bilirubin ≤ 1.5 x ULN, creatinine < 1.5 mg/dL

Concomitant use of somatostatin analogues is allowed for patients with functioning NET.

Exclusion:

• Aggressive disease requiring cytotoxic therapy
• Severe/uncontrolled comorbid conditions that deem participant unfit for everolimus therapy, as per investigators' judgement.
• MiNEN

Procedures:

Randomization 1:1 will be performed centrally by RedCap software at AC Camargo Cancer Center, Sao Paulo, Brasil.

• Group 5 mg: participants will receive everolimus at a dose of 5 mg, orally, per day, continuously
• Group 10 mg group: participants will receive everolimus at a dose of 10 mg, orally, per day, continuously

The participant will receive everolimus 5mg or 10mg and must take 1 (one) tablet, orally, once a day, after breakfast, starting within 4 weeks from randomization. Every 4 weeks of treatment will correspond to 1 treatment cycle. Before starting each cycle, participants will undergo a medical visit to evaluate undesirable effects, medical history, physical examination and check the results of blood tests.

CT scans (or MRI, if applicable) will be performed at every 3 cycles to assess treatment antitumor effect until progression. The treatment will last until tumor progression by RECIST 1.1, intolerance/ severe adverse effects or consent withdrawal.

Participants will be evaluated clinically and with laboratory tests every 4 weeks until resolution of any adverse effects of the treatment. Patients who receive at least one dose of everolimus will be evaluated for the occurrence of toxicities

Sample size:

N=100 patients (50 per arm)

H0= 50% progression free at 12 months H1= 42% progression free at 12 months (inferior value of the 95% CI, based on RADIANT trials) Alpha error (one-sided) = 5% Beta error = 10% Attrition rate = 20%

Inclusion Criteria:

• Histological confirmation of well-differentiated Grade 1/Grade 2 NET from gastrointestinal, pancreatic, pulmonary or unknown primary sites.

• Metastatic or locally advanced and unresectable disease, measurable by images

• Disease progression by RECIST 1.1 in the last 6 months assessed by local investigators

• At least one previous line of systemic treatment (suspended for more than 3 weeks).

• Eastern Cooperative Oncology Group (ECOG) 0-2 o Good organ function:

  • Hemoglobin > 8 g/dL
  • Neutrophils ≥ 1,500/mm³
  • Platelets > 90,000/mm³
  • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN [upper limit of normal] or ≤ 5 x ULN for patients with liver metastases
  • Bilirubin ≤ 1.5 x ULN, creatinine < 1.5 mg/dL

Exclusion Criteria:

• Aggressive disease requiring cytotoxic therapy
• Severe/uncontrolled comorbid conditions that deem participant unfit for everolimus therapy, as per investigators' judgement.
• MiNEN

No plan yet